Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine mouth spray versus cytisine tablet in healthy smokers after overnight abstinence
2016-001267-36Phase 2Completed
- Sponsor
- McNeil Laboratories
- Start
- Apr 2016
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of nicotine and cytisinicline in nicotine dependence (2 arms), sponsored by McNeil Laboratories. Primary endpoints: Mean average urge-to-smoke score change from baseline and Mean reduction in urge-to-smoke score versus baseline. Started Apr 2016; status: completed.
02
Drugs
nicotinecytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2016-001267-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001267-36.